Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford GlycoSciences Plc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (347)	2/22/2003 12:54:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 469

hgsi.com hgsi.com (there is debate about whether or not HGSI was first to describe BLyS. HGSI could do us a favor by reviewing the competitors and their claims.) CATG lists an undisclosed antibody that HGSI has in pre-clinical. HGSI discloses an antibody to VEGF-2. Does anybody know that this antibody is NOT the pipeline Ab? hgsi.com GATG management could make us feel warm and fuzzy by insuring us that the Ab has still not been disclosed by HGSI, that it's not anti-VEGF-2. Note that, while it's listed in at least one table at the HGSI site, anti-TRAIL-R2 is not listed in the pipeline section.